← Back to Search

Norepinephrine-Dopamine Reuptake Inhibitor

Antidepressants for Depression (NBOLD Trial)

Phase 4
Recruiting
Led By David Steffens, M.D., M.H.S.
Research Sponsored by David Steffens
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Major depression, single episode or recurrent
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three years
Awards & highlights

NBOLD Trial Summary

This trial will focus on stress' effect on long-term mood and cognitive outcomes in adults with late-life depression.

Who is the study for?
This trial is for older adults who can read and write English, have a score above 25 on the Mini-Mental State Examination, and are experiencing major depression. It's not suitable for those with lifetime alcohol/drug dependence, untreated endocrine disorders (except diabetes), dementia, or significant brain abnormalities.Check my eligibility
What is being tested?
The study examines how stress affects mood and cognitive outcomes in late-life depression using medications like Sertraline, bupropion, desvenlafaxine. It includes brain imaging to understand the neural basis of these changes.See study design
What are the potential side effects?
Potential side effects from medications such as Sertraline may include nausea, sleepiness or insomnia, headache and sexual dysfunction; bupropion might cause dry mouth, headaches or weight loss; desvenlafaxine could lead to dizziness, insomnia or abnormal sweating.

NBOLD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with major depression.

NBOLD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three years
This trial's timeline: 3 weeks for screening, Varies for treatment, and three years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive clinical diagnosis
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Battery Total Score
Montgomery-Asberg Depression Rating Scale (MADRAS)
Secondary outcome measures
Functional brain magnetic resonance imaging (fMRI) scan changes in resting state functional connectivity.
Functional brain magnetic resonance imaging (fMRI) scan structural imaging changes
Other outcome measures
Neuroticism subtest score on NEO Personality Inventory

NBOLD Trial Design

1Treatment groups
Experimental Treatment
Group I: DepressedExperimental Treatment1 Intervention
Subjects receive FDA-approved antidepressants

Find a Location

Who is running the clinical trial?

David SteffensLead Sponsor
National Institute of Mental Health (NIMH)NIH
2,786 Previous Clinical Trials
2,689,692 Total Patients Enrolled
666 Trials studying Depression
251,509 Patients Enrolled for Depression
David Steffens, M.D., M.H.S.Principal InvestigatorUConn Health

Media Library

Bupropion (Norepinephrine-Dopamine Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05273996 — Phase 4
Depression Research Study Groups: Depressed
Depression Clinical Trial 2023: Bupropion Highlights & Side Effects. Trial Name: NCT05273996 — Phase 4
Bupropion (Norepinephrine-Dopamine Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05273996 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this therapy received official sanctioning by the FDA?

"There is a demonstrated level of safety for this treatment, therefore it receives a score of 3. This is in part due to the fact that the trial has progressed up to Phase 4 and the treatment has already been approved by regulatory bodies."

Answered by AI

Are there any vacant positions available in this clinical trial?

"According to clinicaltrials.gov, the medical study is still looking for candidates and has been since its inception on September 28th 2021 - a fact last confirmed on March 10th 2022."

Answered by AI

How many participants have joined the experiment thus far?

"Absolutely. Clinicaltrials.gov indicates that recruitment is still ongoing for this clinical trial, which was launched on the 28th of September 2021 and last modified on 10th March 2022. The study requires 75 volunteers from a single location."

Answered by AI

Who else is applying?

What site did they apply to?
UConn Health
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Predictors of Cognitive Outcomes in Geriatric Depression
David Steffens 2021. "Predictors of Cognitive Outcomes in Geriatric Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05273996.
All > Depression New York > Wellbutrin
~34 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top